Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized, Double-Blind, Neoadjuvant Study of Hormonal Therapy Plus Palbociclib Versus Hormonal Therapy Plus Placebo in Women With Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer

NCT03969121 is registered in ClinicalTrials.gov with Kyoto Breast Cancer Research Network as lead sponsor.

NCT NCT03969121
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03969121 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized, Double-Blind, Neoadjuvant Study of Hormonal Therapy Plus Palbociclib Versus Hormonal Therapy Plus Placebo in Women With Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
Lead sponsor
Kyoto Breast Cancer Research Network
Phase
Phase 3
Overall status
Completed
Start date
July 16, 2019
Completion date
December 23, 2021
Enrollment
141 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer female, hormone receptor positive malignant neoplasm of breast